SYSTEMATIC REVIEW OF COST EFFECTIVENESS OF GEFITINIB IN THE TREATMENT OF NON-SMALL CELL LUNG CANCER IN CHINA

被引：1
|
作者：
Hu, C. [1 ]
Huang, L. [1 ]
Zhao, D. [1 ]
Xu, L. [1 ]
机构：
[1] Astrazeneca China, Beijing, Peoples R China
来源：
VALUE IN HEALTH | 2015年 / 18卷 / 07期
关键词：
D O I：
10.1016/j.jval.2015.09.1183
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCN166
引用
下载
收藏
页码：A459 / A459
页数：1
相关论文
共 50 条
  • [31] Review of the Treatment of Non-Small Cell Lung Cancer with Gefitinib (vol 6, pg 407, 2012)
    Araki, Takuya
    Yashima, Hideaki
    Shimizu, Kimihiro
    Aomori, Tohru
    Hashita, Tadahiro
    Kaira, Kyoichi
    Nakamura, Tomonori
    Yamamoto, Koujirou
    CLINICAL MEDICINE INSIGHTS-ONCOLOGY, 2013, 7 : 85 - 85
  • [32] Gefitinib or Erlotinib as Maintenance Therapy in Patients with Advanced Stage Non-Small Cell Lung Cancer: A Systematic Review
    Chen, Xiaofeng
    Liu, Yiqian
    Roe, Oluf Dimitri
    Qian, Yingying
    Guo, Renhua
    Zhu, Lingjun
    Yin, Yongmei
    Shu, Yongqian
    PLOS ONE, 2013, 8 (03):
  • [33] Comparing Gefitinib and Traditional Chemotherapy for Better Survival in Patients With Non-Small Cell Lung Cancer: A Systematic Review
    Kanagalingam, Suthasenthuran
    Ul Haq, Zargham
    Srinivasan, Nishok Victory
    Khan, Aujala Irfan
    Mashat, Ghadi D.
    Hazique, Mohammad
    Khan, Kokab Irfan
    Ramesh, Prasana
    Khan, Safeera
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2023, 15 (01)
  • [34] Healthcare outcomes: gemcitabine cost-effectiveness in the treatment of non-small cell lung cancer
    Szczepura, A
    LUNG CANCER, 2002, 38 : S21 - S28
  • [35] Gefitinib (Iressa) trials in non-small cell lung cancer
    Johnson, DH
    LUNG CANCER, 2003, 41 : S23 - S28
  • [36] Gefitinib: an "orphan" drug for non-small cell lung cancer
    Ziogas, Dimitrios C.
    Liontos, Michalis
    Kyriazoglou, Anastasios
    Tsironis, Georgios
    Bamias, Aristotelis
    Dimopoulos, Meletios-Athanasios
    EXPERT OPINION ON ORPHAN DRUGS, 2017, 5 (11): : 899 - 906
  • [37] Gefitinib (Iressa) for advanced non-small cell lung cancer
    不详
    MEDICAL LETTER ON DRUGS AND THERAPEUTICS, 2002, 44 (1138): : 77 - 78
  • [38] COST-EFFECTIVENESS OF GEFITINIB VERSUS DOUBLET CHEMOTHERAPY IN FIRST-LINE TREATMENT OF NON-SMALL CELL LUNG CANCER (NSCLC) IN SWEDEN
    Jacob, J.
    Henriksson, M.
    Brattstrom, D.
    VALUE IN HEALTH, 2010, 13 (07) : A270 - A270
  • [39] A systematic review of non-small cell lung cancer treatment-related cardiotoxicity
    Chan, Stefanie Ho Yi
    Khatib, Yasmin
    Webley, Sherael
    Layton, Deborah
    Salek, Sam
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2021, 30 : 129 - 129
  • [40] Consistency of recommendations for the diagnosis and treatment of non-small cell lung cancer: a systematic review
    Zhang, Zhe
    Yang, Sen
    Ma, Yanfang
    Zhou, Hanqiong
    Wu, Xuan
    Han, Jing
    Hou, Jiabao
    Hao, Lidan
    Spicer, Jonathan D.
    Koh, Young Wha
    Provencio, Mariano
    Reguart, Noemi
    Mitsudomi, Tetsuya
    Wang, Qiming
    TRANSLATIONAL LUNG CANCER RESEARCH, 2021, 10 (06) : 2715 - +
12345